Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer: DNA Sequencing

AFFECTION_STATUS - Case control status of the subject for breast cancer (phv00555771.v1.p1)
IS_TUMOR - Tumor status (phv00555774.v1.p1)
OS_STAT - Overall survival status (event is death by any cause) (phv00555766.v1.p1)
OS_TIME - Time to first event (event is death by any cause) (phv00555767.v1.p1)
PCRAX - Pathologic complete response (pCR) in the breast and axilla (ypT0 or Tis N0) (phv00555770.v1.p1)
PRIMARY_METASTATIC_NORMAL - Primary tumor, metastatic tumor, or normal blood (phv00555777.v1.p1)
STAGE - Clinical tumor stage (II or III) (phv00555768.v1.p1)

ANALYTE_TYPE - Analyte Type (phv00555773.v1.p1)
BEV - Was bevacizumab given? (phv00555764.v1.p1)
BODY_SITE - Body site where sample was collected (phv00555778.v1.p1)
CARBO - Was carboplatin given? (phv00555765.v1.p1)
CONSENT - Consent group as determined by DAC (phv00555757.v1.p1)
HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00555775.v1.p1)
INDRX - Treatment arm (phv00555763.v1.p1)
LOCATION_TYPE - Breast cancer location type (phv00555776.v1.p1)
PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00555779.v1.p1)
SAMPLE_ID - De-identified Sample ID (phv00555772.v1.p1)
SAMPLE_ID - Sample ID (phv00555760.v1.p1)
SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00555782.v1.p1)
STRA1_STAGE - Clinical (pre-NST) stage (phv00555781.v1.p1)
SUBJECT_ID - De-identified subject identification number (phv00555761.v1.p1)
SUBJECT_ID - Subject ID (phv00555756.v1.p1)
SUBJECT_ID - Subject ID (phv00555759.v1.p1)
TUMOR_COLLECTION - Timing of tumor collection, pre or post surgery (phv00555780.v1.p1)